38612460|t|Mechanochemical Approach to Obtaining a Multicomponent Fisetin Delivery System Improving Its Solubility and Biological Activity.
38612460|a|In this study, binary amorphous solid dispersions (ASDs, fisetin-Eudragit ) and ternary amorphous solid inclusions (ASIs, fisetin-Eudragit -HP-beta-cyclodextrin) of fisetin (FIS) were prepared by the mechanochemical method without solvent. The amorphous nature of FIS in ASDs and ASIs was confirmed using XRPD (X-ray powder diffraction). DSC (Differential scanning calorimetry) confirmed full miscibility of multicomponent delivery systems. FT-IR (Fourier-transform infrared analysis) confirmed interactions that stabilize FIS's amorphous state and identified the functional groups involved. The study culminated in evaluating the impact of amorphization on water solubility and conducting in vitro antioxidant assays: 2,2-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)-ABTS, 2,2-diphenyl-1-picrylhydrazyl-DPPH, Cupric Reducing Antioxidant Capacity-CUPRAC, and Ferric Reducing Antioxidant Power-FRAP and in vitro neuroprotective assays: inhibition of acetylcholinesterase-AChE and butyrylcholinesterase-BChE. In addition, molecular docking allowed for the determination of possible bonds and interactions between FIS and the mentioned above enzymes. The best preparation turned out to be ASI_30_EPO (ASD fisetin-Eudragit  containing 30% FIS in combination with HP-beta-cyclodextrin), which showed an improvement in apparent solubility (126.5 +- 0.1 microg mL-1) and antioxidant properties (ABTS: IC50 = 10.25 microg mL-1, DPPH: IC50 = 27.69 microg mL-1, CUPRAC: IC0.5 = 9.52 microg mL-1, FRAP: IC0.5 = 8.56 microg mL-1) and neuroprotective properties (inhibition AChE: 39.91%, and BChE: 42.62%).
38612460	55	62	Fisetin	Chemical	MESH:C017875
38612460	180	184	ASDs	Disease	MESH:C563184
38612460	186	202	fisetin-Eudragit	Chemical	-
38612460	245	249	ASIs	Disease	MESH:C567546
38612460	251	289	fisetin-Eudragit -HP-beta-cyclodextrin	Chemical	-
38612460	294	301	fisetin	Chemical	MESH:C017875
38612460	303	306	FIS	Chemical	MESH:C017875
38612460	393	396	FIS	Chemical	MESH:C017875
38612460	400	404	ASDs	Disease	MESH:C563184
38612460	409	413	ASIs	Disease	MESH:C567546
38612460	652	655	FIS	Chemical	MESH:C017875
38612460	787	792	water	Chemical	MESH:D014867
38612460	848	906	2,2-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)-ABTS	Chemical	-
38612460	908	937	2,2-diphenyl-1-picrylhydrazyl	Chemical	MESH:C004931
38612460	938	942	DPPH	Chemical	MESH:C004931
38612460	944	950	Cupric	Chemical	-
38612460	981	987	CUPRAC	Chemical	-
38612460	993	1020	Ferric Reducing Antioxidant	Chemical	-
38612460	1083	1103	acetylcholinesterase	Gene	43
38612460	1104	1108	AChE	Gene	43
38612460	1113	1134	butyrylcholinesterase	Gene	590
38612460	1135	1140	BChE.	Gene	590
38612460	1245	1248	FIS	Chemical	MESH:C017875
38612460	1320	1330	ASI_30_EPO	Chemical	-
38612460	1332	1335	ASD	Chemical	-
38612460	1336	1352	fisetin-Eudragit	Chemical	-
38612460	1369	1372	FIS	Chemical	MESH:C017875
38612460	1393	1413	HP-beta-cyclodextrin	Chemical	-
38612460	1522	1526	ABTS	Chemical	MESH:C002502
38612460	1554	1558	DPPH	Chemical	MESH:C004931
38612460	1586	1592	CUPRAC	Chemical	-
38612460	1695	1699	AChE	Gene	43
38612460	1713	1717	BChE	Gene	590
38612460	Negative_Correlation	MESH:C017875	590
38612460	Positive_Correlation	MESH:C004931	MESH:C017875
38612460	Negative_Correlation	MESH:C017875	43
38612460	Negative_Correlation	MESH:C017875	MESH:C563184

